In this study we tested the hypothesis that azithromycin therapy would reduce CXCL8 levels, bacterial load and, consequently, neutrophilic inflammation in participants with neutrophilic COPD. The gene discussed is CXCL8; the disease is chronic obstructive pulmonary disease.